Gaudium IVF and Women Health Limited (NSE: GAUDIUMIVF, BSE: 544709) is a New Delhi, Delhi-based company in the Medical Diagnostic Centres industry. With a market capitalisation of ₹803 Cr, it ranks #1,715 by market cap among the 6,197 Indian listed companies on FinBizNet, and #7 of 18 in Medical Diagnostic Centres. At ₹106.70 (as of 16 Nov 2026), the share price is 34.6% below its 52-week high of ₹163.18 and 54.2% above its 52-week low of ₹69.18.
| Current Price | ₹106.70 |
|---|---|
| Market Cap | ₹803 Cr |
| NSE Symbol | GAUDIUMIVF |
| BSE Code | 544709 |
| Sector | Health Care > Health Care Equipment and Services > Health Care Providers and Services |
| Sub-Industry | Health Care Services > Medical Diagnostic Centres |
| P/E Ratio | 27.4 |
| Return on Equity | 16.08% |
| Return on Assets | 15.60% |
| 52-Week Range | ₹69.18 – ₹163.18 |
| 3-Month Price Change | -15.6% |
| Beta (1Y) | 0.77 |
| Headquarters | New Delhi, Delhi |
| Website | www.gaudiumivfcentre.com |
| Revenue | ₹37 Cr |
|---|---|
| Net Profit | ₹9 Cr |
| Net Margin | 25.2% |
| EPS (Basic) | ₹1.29 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Gaudium IVF and Women Health Limited reported revenue of ₹37 Cr in Q2 FY27, up 93.0% from ₹19 Cr in Q1 FY27. It posted a net profit of ₹9 Cr for the quarter, against a net profit of ₹2 Cr in Q1 FY27 (up 428.7%). Across the 4 quarters from Q3 FY26 to Q2 FY27, quarterly revenue ranged from ₹19 Cr (Q1 FY27) to ₹37 Cr (Q2 FY27). The company was profitable in each of these 4 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹37 Cr | ₹9 Cr | 25.2% |
| Q1 FY27 | ₹19 Cr | ₹2 Cr | 9.2% |
| Q4 FY26 | ₹30 Cr | ₹8 Cr | 27.5% |
| Q3 FY26 | ₹25 Cr | ₹4 Cr | 14.8% |
Consolidated figures (₹ crore, XBRL filings).
Promoters held 71.29% of Gaudium IVF and Women Health Limited's shares as of Sept 2026, unchanged from Feb 2026. Delivery averaged 48.7% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
Gaudium IVF and Women Health Limited provides in vitro fertilization (IVF) treatment in India. The company offers fertility and reproductive health services, including intracytoplasmic sperm injection (ICSI), intrauterine insemination (IUI), and ovulation induction; polycystic ovarian syndrome (PCOS)/ polycystic ovarian disease (PCOD); endometriosis treatment; ovulation induction; and laser assisted embryo implantation services. It also provides male infertility treatment services; infertility surgeries; egg freezing; surrogacy; and laparoscopic and hysteroscopic surgeries for the diagnosis and treatment of infertility-related conditions, as well as offers genetic testing options, including preimplantation genetic testing (PGT); and IVF consultancy services. In addition, the company operates hospital, in-house pharmacy; and 7 hubs (IVF centers) and 28 spokes. The company was founded in 2009 and is based in headquartered in New Delhi, India.
1. Healthcare Facilities & Services-This segment provides in vitro fertilization treatment services. 2. NA-NA 3. NA-NA 4. NA-NA
1. Healthcare Facilities & Services-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Dr. Lal Pathlabs Ltd | ₹33,934 Cr | 66.4 | 21.48% | ₹874 Cr | +28.7% |
| Vijaya Diagnostic Centre Limited | ₹14,665 Cr | 84.3 | 19.70% | ₹255 Cr | +38.5% |
| Metropolis Healthcare Limited | ₹11,952 Cr | 61.5 | 13.37% | ₹497 Cr | +14.9% |
| Throcare Technologies Ltd | ₹7,764 Cr | 47.6 | 28.74% | ₹271 Cr | +7.5% |
| SURAKSHA DIAGNOSTIC LIMITED | ₹1,856 Cr | 55.4 | 13.84% | ₹99 Cr | +6.9% |
| Krsnaa Diagnostics Ltd | ₹1,625 Cr | 16.8 | 10.89% | ₹271 Cr | -27.0% |
| Gaudium IVF and Women Health Limited | ₹803 Cr | 27.4 | 16.08% | ₹37 Cr | — |
| Chandan Healthcare Limited | ₹582 Cr | 21.9 | 18.43% | ₹81 Cr | — |
| Aspira Pathlab & Diagnostics Ltd | ₹127 Cr | 2,360 | — | — | +115.2% |
Listed by market capitalisation. Ratios are shown for context only.
Gaudium IVF and Women Health Limited is trading at ₹106.70, with a market capitalisation of ₹803 Cr.
Gaudium IVF and Women Health Limited operates in the Health Care > Health Care Equipment and Services > Health Care Providers and Services space (Health Care Services > Medical Diagnostic Centres).
Gaudium IVF and Women Health Limited has a P/E of 27.4 and a return on equity of 16.08%.
Gaudium IVF and Women Health Limited is listed on the NSE under the symbol GAUDIUMIVF and on the BSE under the scrip code 544709.
In Q2 FY27, Gaudium IVF and Women Health Limited reported revenue of ₹37 Cr and net profit of ₹9 Cr, with basic EPS of ₹1.29 (consolidated, parsed from the company's exchange filing).
Promoters held 71.29% of Gaudium IVF and Women Health Limited's shares as of Sept 2026, unchanged from Feb 2026.
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.